RE:Anyone else seeing this?That would certainly make this product the game changer that many of us here have bet on.. Also of note will be the potential follow up study to the re addmission study looking at modifying treatments to delay or avoid re addmissions.. This study has the potential to revolutionize how cardiac patients are assessed and save the healthcare system billions of dollars by reducing re-admission rates as more appropriate therapy is applied to those patients in left-heart failure with right-heart involvement. It is estimated that avoidable cardiac readmissions cost the US healthcare system $17.6B per year
Read more at https://www.stockhouse.com/companies/bullboard/v.vpt/ventripoint-diagnostics-ltd#B3UFlWDeQppC19g5.99